Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-07-28

Clinical Trial Update: A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664) [Phase 3]

View source ↗

Summary

Phase 3 trial of preladenant in early Parkinson's disease was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • preladenant (preladenant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Parkinson Disease | Phase 3 | Status: TERMINATED | Results posted: 2016-07-28